Anti-Malarial Medicines

Anti-Malarial Medicines

Global Anti-Malarial Medicines Market to Reach US$1.2 Billion by 2030

The global market for Anti-Malarial Medicines estimated at US$960.2 Million in the year 2023, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2023-2030. Antifolate Compounds, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$462.8 Million by the end of the analysis period. Growth in the Aryl Aminoalcohol Compounds segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$261.6 Million While China is Forecast to Grow at 5.3% CAGR

The Anti-Malarial Medicines market in the U.S. is estimated at US$261.6 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$231.7 Million by the year 2030 trailing a CAGR of 5.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.3% CAGR.

Global Anti-Malarial Medicines Market - Key Trends and Drivers Summarized

The treatment and control of malaria heavily depend on effective anti-malarial drugs. These medications are crucial not only for curing the infected but also for reducing the transmission of the disease, especially in regions with low transmission. Anti-malarial treatments such as artemisinin combination therapies (ACTs) have been instrumental in managing falciparum malaria by targeting both the symptomatic asexual stages and the more resistant sexual stages (gametocytes) of the parasite. Primaquine, in particular, has been effective against Plasmodium vivax and ovale by targeting the dormant liver stages and preventing relapses. However, the use of primaquine raises concerns due to its potential severe side effects in people with G6PD deficiency, a common condition in malaria-endemic areas. The challenge remains to balance effective treatment while minimizing adverse effects, especially without comprehensive screening for G6PD deficiency.

The distribution and efficacy of anti-malarial drugs are affected by numerous factors, including drug resistance which has become a significant barrier in malaria control. Resistance to older drugs like chloroquine and sulfadoxine-pyrimethamine has led to the increased use of ACTs. However, the emergence of resistance to these newer treatments could undermine recent gains in malaria control. Epidemiological studies suggest that while high transmission regions can buffer the impact of resistance due to a mix of infected individuals and immunity levels, low transmission areas may see a quicker spread and establishment of resistant strains due to fewer infections and lower immunity. Therefore, ongoing monitoring and adapting drug policies based on resistance patterns are crucial for maintaining drug efficacy. Furthermore, innovations in pharmaceutical technology that improve drug action and delivery are vital for staying ahead of resistance.

The growth in the anti-malarial drug market is driven by several factors including advancements in pharmaceutical technologies which lead to more effective and safer formulations, and the rising resistance to existing medications which necessitates continuous development of new drugs. Government and non-governmental organizations play crucial roles in enhancing drug distribution and promoting public health initiatives that support malaria control programs. Public health policies and programs that include mass drug administration and preventive treatments help reduce the burden of malaria. Additionally, the expansion of healthcare infrastructure in endemic regions ensures better drug availability and treatment coverage. Changes in climate patterns that potentially expand malaria zones also increase the demand for effective anti-malarial drugs in new regions. Lastly, increased consumer awareness and education about malaria prevention and treatment options drive the demand for these essential medications.

Select Competitors (Total 48 Featured) -

• Alvizia Healthcare
• Dewcare Concept Pvt. Ltd
• Eisai Co., Ltd.
• GSK plc
• Ipca Laboratories Ltd
• Lincoln Pharmaceuticals Ltd.
• Merck KGaA
• Novartis AG
• Pfizer, Inc.
• Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
• Strides Pharma Science Limited
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd
• Viatris Inc.
• Zydus Lifesciences Limited;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.